Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders

2013 ◽  
Vol 113 (5) ◽  
pp. PR123-PR178 ◽  
Author(s):  
Na Ye ◽  
John L. Neumeyer ◽  
Ross J. Baldessarini ◽  
Xuechu Zhen ◽  
Ao Zhang
Keyword(s):  
Psychiatric Disorders ◽  
Dopamine Receptor ◽  
Recent Progress ◽  
Receptor Subtype ◽  
Selective Agents ◽  
Subtype Selective ◽  
Potential Therapeutics

scholarly journals Comparison of the Binding and Functional Properties of Two Structurally Different D2 Dopamine Receptor Subtype Selective Compounds

2012 ◽  
Vol 3 (12) ◽  
pp. 1050-1062 ◽  
Author(s):  
Robert R. Luedtke ◽  
Yogesh Mishra ◽  
Qi Wang ◽  
Suzy A. Griffin ◽  
Cathy Bell-Horner ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
Functional Properties ◽  
Receptor Subtype ◽  
D2 Dopamine Receptor ◽  
Subtype Selective

scholarly journals Evaluation of Substituted N-Phenylpiperazine Analogs as D3 vs. D2 Dopamine Receptor Subtype Selective Ligands

Molecules ◽  
2021 ◽  
Vol 26 (11) ◽  
pp. 3182
Author(s):  
Boeun Lee ◽  
Michelle Taylor ◽  
Suzy A. Griffin ◽  
Tamara McInnis ◽  
Nathalie Sumien ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
Involuntary Movement ◽  
Receptor Subtype ◽  
Receptor Subtypes ◽  
Inhibition Assay ◽  
D2 Dopamine Receptor ◽  
Selective Ligand ◽  
6 Hydroxydopamine ◽  
Subtype Selective

N-phenylpiperazine analogs can bind selectively to the D3 versus the D2 dopamine receptor subtype despite the fact that these two D2-like dopamine receptor subtypes exhibit substantial amino acid sequence homology. The binding for a number of these receptor subtype selective compounds was found to be consistent with their ability to bind at the D3 dopamine receptor subtype in a bitopic manner. In this study, a series of the 3-thiophenephenyl and 4-thiazolylphenyl fluoride substituted N-phenylpiperazine analogs were evaluated. Compound 6a was found to bind at the human D3 receptor with nanomolar affinity with substantial D3 vs. D2 binding selectivity (approximately 500-fold). Compound 6a was also tested for activity in two in-vivo assays: (1) a hallucinogenic-dependent head twitch response inhibition assay using DBA/2J mice and (2) an L-dopa-dependent abnormal involuntary movement (AIM) inhibition assay using unilateral 6-hydroxydopamine lesioned (hemiparkinsonian) rats. Compound 6a was found to be active in both assays. This compound could lead to a better understanding of how a bitopic D3 dopamine receptor selective ligand might lead to the development of pharmacotherapeutics for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.

Dopamine-Receptor Subtype-Selective Agonists in the Treatment of Parkinsonʼs Disease

1995 ◽  
Vol 18 ◽  
pp. S207-S215 ◽  
Author(s):  
Thomas N. Chase ◽  
Verhagen L. Metman ◽  
D. Bravi ◽  
J. W. Roberts ◽  
D. R. Sibley ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
Receptor Subtype ◽  
Selective Agonists ◽  
Subtype Selective

Dopamine Receptor Subtype-Selective Drugs: D2-Like Receptors

2009 ◽  
pp. 101-135
Author(s):  
Olaf Prante ◽  
Miriam Dörfler ◽  
Peter Gmeiner
Keyword(s):  
Dopamine Receptor ◽  
Receptor Subtype ◽  
Subtype Selective
Sign in / Sign up

Export Citation Format

Share Document